Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference46 articles.
1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al (2020) Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 76(25):2982–3021
2. Hsia DS, Grove O, Cefalu WT (2017) An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 24(1):73–79
3. Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17(12):761–772
4. Tamez-Perez HE, Delgadillo-Esteban E, Soni-Duque D, Hernández-Coria MI, Tamez-Peña AL (2017) SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study. J Diabetes Metab Disord 16:27
5. Li C, Luo J, Jiang M, Wang K (2022) The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol 13:838277
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献